Iaquinto Stefania, Ineichen Benjamin Victor, Stanikić Mina, Kuhle Jens, Kamm Christian Philipp, Calabrese Pasquale, Roth Patrick, Baum Claudia, Zecca Chiara, Gobbi Claudio, Yaldizli Özgür, Puhan Milo Alan, von Wyl Viktor
Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Department of Clinical Research, University of Bern, Bern, Switzerland.
Eur J Neurol. 2025 Jun;32(6):e70230. doi: 10.1111/ene.70230.
Monitoring multiple sclerosis (MS) progression traditionally relies on clinical measures, which may overlook symptoms affecting quality of life. Incorporating patient-reported outcomes could improve the understanding of disease worsening.
To evaluate an EQ-5D-based algorithm for detecting disease worsening and compare it with EDSS worsening.
We analyzed longitudinal EQ-5D and EDSS data from the Swiss MS Registry. EQ-5D worsening was defined as a sustained decline over two assessments; EDSS worsening followed established clinical criteria. Time to confirmed worsening was assessed using Kaplan-Meier curves and Cox regression. Patterns in 12 self-reported symptoms were examined using descriptive statistics and logistic regression.
By year four, 4.5% experienced EQ-5D worsening, while 15.8% experienced EDSS worsening. Faster time to EQ-5D worsening was associated with walking aids or higher BMI at baseline. Conversely, faster time to EDSS worsening was associated with male sex, progressive MS, or spasms as the first symptom. Symptom frequency was higher in the EQ-5D worsening group, with pain and depression independently associated, while no symptoms were associated with EDSS worsening.
While EQ-5D worsening does not serve as an early clinical marker of disease progression, it may complement EDSS by capturing additional aspects of disease progression, particularly symptoms impacting HRQoL, that are not reflected in EDSS progression. Long-term HRQoL monitoring alongside traditional measures may improve MS progression assessment and patient-centered care.
传统上,监测多发性硬化症(MS)的进展依赖于临床指标,而这些指标可能会忽略影响生活质量的症状。纳入患者报告的结果可能会增进对疾病恶化的理解。
评估一种基于EQ-5D的疾病恶化检测算法,并将其与扩展残疾状态量表(EDSS)恶化情况进行比较。
我们分析了瑞士MS注册中心的纵向EQ-5D和EDSS数据。EQ-5D恶化定义为在两次评估中持续下降;EDSS恶化遵循既定的临床标准。使用Kaplan-Meier曲线和Cox回归评估确诊恶化的时间。使用描述性统计和逻辑回归检查12种自我报告症状的模式。
到第四年,4.5%的患者出现EQ-5D恶化,而15.8%的患者出现EDSS恶化。EQ-5D恶化时间较快与基线时使用助行器或较高体重指数相关。相反,EDSS恶化时间较快与男性、进展型MS或首发症状为痉挛相关。EQ-5D恶化组的症状频率更高,疼痛和抑郁独立相关,而没有症状与EDSS恶化相关。
虽然EQ-5D恶化不能作为疾病进展的早期临床标志物,但它可能通过捕捉疾病进展的其他方面来补充EDSS,特别是那些影响健康相关生活质量(HRQoL)但未在EDSS进展中体现的症状。与传统指标一起进行长期HRQoL监测可能会改善MS进展评估和以患者为中心的护理。